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Peversal of Calcium Cycling
efects in Advanced Heart Failure
oward Molecular Therapy
asahiko Hoshijima, MD, PHD,*† Ralph Knöll, MD, PHD,* Mohammad Pashmforoush, MD, PHD,*
enneth R. Chien, MD, PHD,*‡
a Jolla, California; and Boston, Massachusetts
Heart failure is a growing major cause of human morbidity and mortality worldwide. A wave
of new insights from diverse laboratories has begun to uncover new therapeutic strategies that
affect the molecular pathways within cardiomyocytes that drive heart failure progression.
Using an integrative approach that employs insights from genetic-based studies in mouse and
humans and in vivo somatic gene transfer studies, we have uncovered a new link between
stress signals mediated by mechanical stretch and defects in sarcoplasmic reticulum (SR)
calcium cycling. An intrinsic mechanical stress sensing system is embedded in the Z disc of
cardiomyocytes, and defects in stretch responses can lead to heart failure progression and
associated increases in wall stress. Reversal of the chronic increases in wall stress by promoting
SR calcium cycling can prevent and partially reverse heart failure progression in multiple
genetic and acquired model systems of heart failure in both small and large animals. We
propose that reversal of advanced heart failure is possible by targeting the defects in SR
calcium cycling, which may be a final common pathway for the progression of many forms of
heart failure. (J Am Coll Cardiol 2006;48:A15–23) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.070Cardiology Foundation
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por heart failure patients and their physicians, these are the
est of times and the worst of times. Over the past 3
ecades, there have been major advances in the treatment of
eart failure, ranging from an extensive list of medical
herapy (beta-blockers, angiotensin-converting enzyme in-
ibitors, and so on), improvements in heart transplantation
ith new agents to suppress tissue rejection, and novel
evice technology (synchronized pacing/left ventricular as-
ist devices, and so on). At the same time, despite these
ubstantial clinical advances, heart failure has become the
ajor cause of human cardiovascular morbidity and mor-
ality worldwide, and has been predicted to reach epidemic
roportions in the early period of the 21st century. The
easons for this clinical conundrum are undoubtedly multi-
actorial, reflecting the increasing lifespan, globalization of
alorie-rich eating habits, the higher incidence of metabolic
iseases and associated risk for ischemic heart disease, and
he substantial improvement of the survival rate of acute
oronary events. In fact, an exponential increase in the
ncidence of heart failure in China and India, followed by
any other countries, is signaling an emerging global health
roblem of unprecedented proportions (1,2). At the core of
his epidemic is our fundamental lack of understanding of
he precise molecular pathways that drive human heart
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ccepted June 22, 2006.ailure (i.e., mechanisms underlying the progressive dilation
f the cardiac chamber and the associated decreases in
ardiac contractility). However, several laboratories have
uccessfully utilized an integrative approach to dissect path-
ays that lead to dilated cardiomyopathy (DCM), employ-
ng genetic-based studies in mice and humans, in vivo
omatic gene transfer, bioinformatics, advanced imaging
echnologies, and computational biology, which is begin-
ing to provide new insights into the disease process, and
uggesting new therapeutic targets and strategies for inter-
ening in the disease (3–7). Accordingly, a growing body of
vidence suggests that a major component of this process
ow appears to be chronic increases in wall stress that
rigger specific stress-related signaling pathways for critical
ell responses, which include cell death pathways, survival
ues, hypertrophic responses, and associated changes in the
ownstream pathways (8,9). In this review, we describe
ecent advances that have lead to the discovery of a pivotal
ole of defects in calcium cycling in the pathogenesis of
uman heart failure and the background that has led to a
ovel therapeutic strategy for reversal of these defects that
ill be slated for clinical studies in the coming year.
HARACTERIZATION OF A GENETICALLY
ASED MODEL OF DCM AND HEART FAILURE IN
USCLE-SPECIFIC LIM PROTEIN (MLP)-DEFICIENT MICE
ne of the first genetic links between cardiac cytoskeletal
efects and DCM was made via studies of mutant mice that
arbor a deficiency in MLP (10). Muscle-specific LIM
rotein, also known as cysteine-rich protein 3 or cysteine-
nd glycine-rich protein 3 (CSRP3), is a member of the
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Reversal of Calcium Defects in Heart Failure November 7, 2006:A15–23-reactive protein gene family (11) and contains 2 highly
onserved LIM domains that have been shown to serve as
rotein-protein interaction modules in a series of LIM
roteins (12). Muscle-specific LIM protein is expressed in
ardiac and skeletal muscle (10,13) and is predominantly
ocalized in the cardiac cytoskeleton, mainly adjacent to the
disc structure (10,14). Mutant mice with the genetic
blation of MLP display a cardiac phenotype that closely
esembles human DCM, including progressive enlargement
f all 4 cardiac chambers, ventricular wall thinning, decreases in
ardiac contractility (10,15), induction of embryonic gene
arkers, defects in sarcoplasmic reticulum (SR) Ca2 han-
ling (15,16), with the elongation of action potential dura-
ion and the desensitization of beta-adrenergic signaling
10,17) (Fig. 1). In addition, genetic defects of CSRP3/
LP (18–20) and abnormal CSRP3/MLP expression (21)
ave been linked to cardiomyopathy and heart failure in
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CM  cardiomyopathic
CSRP3  cysteine- and glycine-rich protein 3
DCM  dilated cardiomyopathy
HCM  hypertrophic cardiomyopathy
MLP  muscle-specific LIM protein
PKA  protein kinase A
PLN  phospholamban
post-MI  post-myocardial infarction
rAAV  recombinant adeno-associated virus
RyR  ryanodine receptor
SERCA2  sarcoplasmic reticulum calcium ATPase 2
SR  sarcoplasmic reticulum
T-cap  titin-cap
TTN  titin
igure 1. Muscle-specific LIM protein (MLP)-deficient (MLPKO) mi
ardiomyopathy (DCM). Note defective Z disc found in the MLP-null myoca
AR  beta-adrenergic receptor.uman patients. Thus, the MLP-null mouse serves as an
deal tool for unraveling pathways that lead to heart failure
nitiation and progression, as well as the identification of
ew therapeutic strategies via genetic complementation.
N MLP/TITIN-CAP (T-CAP)/Z DISC
ITIN COMPLEX CONSTITUTES AN ESSENTIAL
OMPONENT OF THE INTRINSIC MECHANICAL
TRESS SENSOR MACHINERY IN CARDIOMYOCYTES
tilizing the MLP-null mouse model of cardiomyopathy, we
evealed a critical role for MLP as an essential component of
he cardiac muscle stretch sensor (18). A combinatorial ap-
roach of yeast 2-hybrid screening of a cardiac cDNA library,
lutathione S-transferase-pull down, and immuno-co-
ocalization analyses identified a 19-kD cytoskeletal protein,
-cap (T-cap: telethonin), as a MLP-binding protein. This
olecule localizes at the sarcomere Z disc and binds to the
H2-terminal Z disc domain of the titin molecule (Fig. 2).
he T-cap interacting domain of MLP was identified in a
hort NH2-terminal domain of MLP that precedes the first
IM domain (18). Immuno-staining of T-cap in the
LP-null myocardium demonstrated that T-cap was dis-
ociated from Z disc and diffused out in the cytoplasm in a
raction of cardiomyocytes, indicating the possibility that
LP stabilizes T-cap interaction with the NH2-terminal Z
isc-associated domain of titin. In addition, electric-
icroscopic examination of MLP-null myocardium dem-
nstrated that the MLP-null Z disc was widened, brushed,
nd wavy compared with wild-type control animals.
Titin serves a structural role in cardiac muscle in sarco-
eric organization and assembly, as well as playing a crucial
ole in restoring cardiac sarcomeric length and in aligning
he M-band at the center of the sarcomere during each
are a broad spectrum of pathological phenotypes with human dilatedce sh
rdium. APD  action potential duration; SR  sarcoplasmic reticulum;
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November 7, 2006:A15–23 Reversal of Calcium Defects in Heart Failureardiac contraction (22,23). Titin is anchored at the Z disc
ith its NH2-terminal strongly associated with the actin
hin filament that is cross-linked by -actinin. Interestingly,
n vitro physiological measurements revealed that MLP-null
ardiac papillary muscles from 2-week-old MLP-null mice
before the development of general cardiac dysfunction),
isplayed a selective defect in the mechanical stretch prop-
rties of titin, with impairment in tension generation starting
t a short range (within 10%) of passive stretch (18). Further-
ore, cultured MLP-deficient neonatal day 1 to 3 cardiac
uscle cells displayed a nearly complete loss of passive stretch-
ependent induction of a genetic marker of cardiac mechanical
tress, brain natriuretic peptide (BNP) (18). Importantly,
he same MLP-null cardiomyocytes retained a normal BNP
nduction in response to G-protein coupling membrane
eceptor stimulation, providing direct support for a selective
efect in mechanical stress sensing functions in MLP-null
ardiac muscle. Taken together, our studies in MLP-null
ardiomyocytes revealed that an MLP interaction with
-cap at the Z disc is critical to maintain the mechanical
lastic properties of titin and that MLP/T-cap/Z disc-titin
omplex constitutes a critical molecular component of the
ardiac muscle stretch sensor (24). In this manner, a loss or
igure 2. Z disc-related mechanical sensor cross-talks with receptor-depen
rbB2-erbB4, and insulin-like growth factor-1 receptor (IGF1-R) activate
alcium-activated calcineurin dephosphorylates multiple cellular substr
ardiomyocytes, on the other hand, have (perhaps multiple) mechanical str
MLP) complex constitutes such a sensor systems associated with Z discs (2
KK  mitogen-activated protein kinase kinase; PDK1  phosphoinosi
ransducer and activator of transcription-3.ysfunction of this intrinsic mechanical stress sensing machin- gry linked to the Z disc-titin structure may lead to the
evelopment of heart failure and DCM via the loss of the
bility to activate stretch-mediated survival cues. Such survival
ues could occur via the gp130-dependent, neurgulin-ErbB2/
rbB4-induced, or insulin-like growth factor-1-activated car-
iomyocyte survival pathway (25–29) (Fig. 2), or calcineurin-
ependent pro-hypertrophic nuclear gene regulatory
athway (30).
SRP3/MLP MUTATIONS
SSOCIATED WITH FAMILIAL DILATED
ND HYPERTROPHIC CARDIOMYOPATHIES (HCMS)
ince the discovery of the MLP mouse model of DCM, a
rowing list of genetic defects have been found in cytoskel-
tal proteins (7,31), as well as in extracellular matrix proteins
hat serve an anchoring function with the sarcolemmal
ytoskeletal complex (32), linking them to the familial forms
f cardiomyopathies. CSRP3 (human MLP) is encoded by
n approximately 20-kb genomic sequence with 6 exons.
e started with sequencing the CSRP3 coding exons of
enomic DNAs obtained from selected DCM patients,
ollowed by polymerase chain reaction–based selective sin-
signaling. Transmembrane receptors including gp130 cytokine receptors,
iple signal kinase cascades that regulate cell protective gene programs. A
including transcriptional regulators that regulate cardiac remodeling.
nsors inside of the cells, and the titin-T-cap-muscle-specific LIM protein
kt protein kinase B; Jak Janus kinase; MAP mean arterial pressure;
ependent protein kinase 1; SR  sarcoplasmic reticulum; Stat3  signaldent
mult
ates
ess se
4). Ale nucleotide change analyses for 536 well-phenotyped
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Reversal of Calcium Defects in Heart Failure November 7, 2006:A15–23aucasian patients bearing familial DCM together with 320
ontrol individuals with the same demographic distribution.
onsequently, we identified a close association between 10
f 536 human DCM patients and a sense nucleotide
lteration of CSRP3 (i.e., CSRP3[W4R]) in a highly
onserved amino acid residue within the N-terminal T-cap
inding domain (18). The linkage analysis in these families
s limited by several factors, including the size of available
edigrees and age-dependent penetrance. Interestingly, the
aplotype analysis supported a founder effect in a DCM
atient population with CSRP3(W4R), although there
ere no linking records of affinity between patient families.
After the publication of our original report, at least 3 studies
ave analyzed CSRP3(W4R) in DCM and HCM patients.
ne study found CSRP3(W4R) in a family with DCM;
owever, CSRP3(W4R) did not segregate with DCM in this
amily (20). In another study, CSRP3(W4R) was found in 7 of
89 unrelated HCM patients with 1 in 400 reference alleles,
nd, interestingly, 3 HCM patients with CSRP3(W4R) also
arried mutations of either beta-myosin heavy chain or myosin
inding protein-C (33). Finally, a Canadian study reported 1
CM patient with CSRP3(W4R) of 192, whereas
SRP3(W4R) was also found in 3 of 250 control individuals,
ho are predominantly of British Isles origin and did not
eceive formal cardiologic examination (34). Accordingly, it is
lausible that CSRP3(W4R) is a genetic modifier or a rela-
ively rare polymorphism that segregates with a subset of the
ardiomyopathy population, rather than a disease-causing vari-
nt. Besides the W4R variant, other nucleotide changes
L44P, S54R/E55G, C58G, K69R) in the CSRP3 gene have
ecently been reported in patients with cardiomyopathies
19,20). The amino acid positions of these additional muta-
ions are outside of the T-cap interacting domain of CSRP3.
Although genetic evidence is somewhat obscure, there
as a strong biological finding to support the role of the
SRP3(W4R) amino acid substitution in the pathogenesis
f DCM. The CSRP3(W4R) resulted in the complete loss
f T-cap interaction shown by the yeast 2-hybrid analysis,
nd myocardial biopsies from a DCM patient harboring a
SRP3(W4R) allele showed partial T-cap dissociation
rom the Z disc. The biological significance of MLP/T-cap
nteraction in the maintenance of normal cardiac function
as further emphasized by our independent identification of
single proband with the R87Q mutation of TCAP (human
-cap gene) in a set of Caucasian DCM patients (18). The
87 amino acid residue was mapped within the MLP-
nteracting domain of T-cap, and TCAP(R87Q) mutant
rotein displayed a 80% reduction in binding affinity to
LP (35). Interestingly, other mutations in TCAP are linked
o Limb-Girdle Muscular Dystrophy type 2G (36), suggesting
hat T-cap interaction with the Z disc-titin structure is
equisite to maintain physiological functions of both cardiac
nd skeletal muscle. Herein, human titin (TTN) mutations
ave been linked to familial DCM (37,38), and a mutation was
lso found in an HCM patient (39). As a recent study proposes
model of N-terminal titin assembly that is mediated by the mimerization of T-cap in an antiparallel manner (40), we
peculate that mutations of CSRP3, TCAP, and TTN share a
ommon molecular pathway to induce and/or modulate the
evelopment of cardiomyopathy.
DENTIFICATION OF SR
ALCIUM CYCLING AS A MAJOR
ARGET TO TREAT DCM AND HEART FAILURE:
HOSPHOLAMBAN (PLN) ABLATION RESCUES HEART
AILURE IN THE SUBSETS OF MOUSE MODELS OF DCM
efects in SR Ca2 cycling are a highly conserved signature
eature of experimental and human heart failure. The most
otable abnormalities are a decrease in the Ca2 re-entry
echanism into the SR, which is predominantly governed
y the activity of the SR calcium ATPase 2 (SERCA2) and
ysregulated Ca2 release from SR through ryanodine
eceptor (RyR) (Fig. 3A). In both cases, the SR calcium
evel is largely diminished in failing hearts, creating defects
n both diastolic and systolic functions. In this manner, a
ecrease in the quantal release of calcium from SR through
yR during systole affects the contractility of individual
ardiomyocytes, whereas the impaired calcium pump func-
ion results in a defect in ventricular relaxation. Cardiac
uscle cells have an endogenous inhibitor of SERCA2,
amely PLN, which is a highly conserved 52-amino-acid
eptide and the expression of which is largely restricted in
he heart and slow skeletal muscle. Phospholamban is
hosphorylated by the cyclic adenosine monophosphate
AMP)-dependent protein kinase (PKA) that is regulated
y G-protein coupling receptors including -adrenergic
eceptors, and this phosphorylation in turn releases the PLN
nhibitory effects on the SERCA2 activity (41,42). In many
orms of human and experimental heart failure, the down-
egulation of the SERCA2 expression level, impairments in
he SERCA2/PLN ratio, and a decrease in the phosphor-
lated form of PLN have been documented (42–44).
hether these changes are part of abnormal cardiac remod-
ling in the development of heart failure or represent an
daptive process to limit cardiac function and reduce cardiac
nergy consumption to protect cardiomyocytes has been a
oint of discussion. To address this question, we utilized a
enetic complementation strategy, which ultimately pro-
ided strong evidence that defects in SR Ca2 cycling play
pivotal role in heart failure progression. We generated
ouble knockout mice, which harbor the MLP-null cardio-
yopathic mutation, but also lack PLN, and subsequently
xamined whether removing PLN inhibition alone would
ave a measurable effect on heart failure progression. Re-
arkably, the ablation of PLN completely prevented the
pectrum of heart failure phenotypes found in a mouse
odel of DCM caused by MLP deficiency (16).
Subsequent studies designed to test PLN ablation in
arious forms of cardiomyopathy and heart failure reported
ixed results (45–47). In some forms of transgenic cardio-
yopathy mouse models, PLN-null rescued cardiomyopa-
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November 7, 2006:A15–23 Reversal of Calcium Defects in Heart Failurehy phenotypes, while benefits were unclear in other model
ystems. Obviously there are limitations to the use of
enetically based models to validate new therapeutic strat-
gies for acquired forms of human heart failure. Indeed,
ost of these models have not been validated with respect to
heir fidelity of predicting therapeutic efficacy in the clinical
etting. Furthermore, it would be pivotal to evaluate the
igure 3. Regulatory systems of cardiac excitation-contraction coupling an
ntracellular mobilization of calcium ions governs myofilament contraction
yanodine receptor (RyR), and a regulator of SR calcium uptake, phosphol
second-messenger-regulated kinases, cyclic adenosine monophosphate (
CaMKII) (42). S16EPLN therapy directly targets SR calcium uptake (see
(SERCA2) regulation has been refined, based on recent studies by Mu
ERCA2 due to their low dissociation constant. Physiologically, high calc
he cytoplasmic domain of PLN, which results in a structural rearrangemen
ithout dissociation. S16EPLN structurally resembles the Ser16-phosphoy
ERCA2-S16EPLN complex in cardiomyocytes. ARK  adrenergic rece
CX  Na-Ca exchanger.ffects of the reversal of the calcium cycling defect on heart pailure after it had already been fully established as opposed
o examining effects to prevent the initial onset. In this
egard, as described in subsequent sections, we tested the
LN inhibitory therapy in 2 well-established and fully
alidated small animal heart failure models; one is a genetic
orm and the other is surgically induced, both of which have
long history of extensive use for a wide variety of
gene therapy targeting sarcoplasmic reticulum (SR) calcium uptake. (A)
relaxation. Two calcium release channels, the L-type calcium channel and
n (PLN), are key controllers of calcium mobilization under the control of
)-dependent kinase (PKA) and calcium-calmodulin-dependent kinase II
or details). (B) A working model of PLN-dependent SR calcium ATPase
et al. (61) and Zamoon et al. (62). Phospholamban is tightly bound to
oncentration or PLN phosphorylation induces conformational changes of
LN-SERCA2 interaction (from an inactive complex to an active complex)
form PLN. Thus, S16EPLN transfection may stably constitute an active
inase; AR  beta-adrenergic receptor; FKBP  K506 binding protein;d the
and
amba
AMP
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ptor kharmacological therapy. In both cases, PLN inhibition was
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Reversal of Calcium Defects in Heart Failure November 7, 2006:A15–23nduced by cardiac-targeted somatic gene transfer (Fig. 3A),
ubstantially after the onset of heart failure and during its
isease progression, to allow a direct examination as to
hether improvement of calcium cycling defects might lead
o a reversal of components of the heart failure phenotype.
LN INHIBITION RESCUES HEART FAILURE
N THE HAMSTER MODEL OF LIMB-GIRDLE
USCULAR DYSTROPHY AND CARDIOMYOPATHY
o allow long-term, high efficiency, in-vivo transcoronary delivery
nd expression of foreign genes, we first developed a new
ranscoronary gene delivery system that utilized a recombinant
deno-associated virus (rAAV) vector (48). The therapeutic pay-
oad of the vector was a PLN inhibitory peptide, which consisted
f a pseudo-phosphorylated mutant of PLN with a single amino-
cid change at the position Ser16 to Glu (S16EPLN), designed to
imic the conformational change in PLN after phosphorylation
y PKA (Fig. 3B). This S16EPLN/rAAV vector was then used
o constitutively activate SR Ca2 cycling in the myocardium of
he well-characterized small animal model of chronic heart failure
nd DCM, the BIO14.6 cardiomyopathic (CM) hamster, which
s based on a mutation in the -sarcoglycan gene. This genetic
efect represents an autosomal recessive form of human myopathy
ound in limb-girdle muscular dystrophy type F (49). Although
ardiac involvement of human limb-girdle muscular dystrophy is
enerally mild, -sarcoglycan deficiency in small animals including
he BIO14.6 CM hamster and its derivatives and -sarcoglycan
nockout mice causes an aggressive form of cardiomyopathy
50,51). Although there is an ongoing debate whether sarcolem-
al defects in cardiomyocytes are a primary cause of
-sarcoglycan-null cardiomyopathy or vascular abnormality
ontributes to its pathogenesis (52–54), sarcolemmal fragility
ay be a common pathological process of cardiomyopathies
hat are induced by genetic defects of cortical cytoskeletal
roteins (52,53) or their secondary defects (55). Interstitial and
eplacement fibrosis also contributes to the pathological
rocess of cardiomyopathy in BIO14.6 CM hamsters
52,53).
Nevertheless, the chronic inhibition of PLN by the
16EPLN peptide resulted in a marked enhancement of
ardiac diastolic and systolic function even at advanced
tages of the disease over 7 months from the initial delivery
f the gene (48). Accordingly, the S16EPLN was capable of
nducing the stable activation of SERCA2 and resulted in the
nhancement of cardiac relaxation and subsequent contractility
n the absence of adrenergic stimuli, which was analogous to
he null phenotype of the PLN mutant mice (16).
LN INHIBITION RESCUES
EART FAILURE DEVELOPMENT
N THE RAT MODEL OF POST-MYOCARDIAL
NFARCTION (POST-MI) CHRONIC HEART FAILURE
he rAAV-mediated pseudo-phosphorylated PLN gene
ransfer therapy was tested in the chronic failing hearts of nost-MI rats (56). Pre-gene transfer echocardiography doc-
mented that the recipient mouse (5 weeks after myocardial
nfarction surgery, with 30% to 40% infarction size
elected by echocardiography) had a moderate level of heart
ailure with the average percent fractional shortening as
2.4%, compared with the sham control animals (average
ercent fractional shortening, 53.1%). Eighty-five percent
nimals survived the gene transfer procedure, which was
ostly similar to that used for the preceding BIO14.6 CM
amster studies, and the therapeutic prognosis was evalu-
ted by repeated echocardiography over 6 months (Figs. 4A
o 4F).
The left ventricular ejection fraction was enhanced by
.0% at 2 months compared with the pre-gene transfer
aseline value and by 12.8% at 6 months in S16EPLN-
reated MI-rats, in contrast with the progressive decline of
eft ventricular ejection fraction in saline-treated control
ost-MI animals (Fig. 4C). Change in the left ventricular
nd-diastolic volume of S16EPLN-treated rat from the pre-
ene transfer to the end point was limited to 18.2%, which was
ndistinguishable with sham rats and was considered propor-
ional to the natural growth of animals (Fig. 4A), suggesting
he complete suppression of progressive left ventricular
ilation by the S16EPLN therapy in post-MI rats (note the
eft ventricles of saline-treated control post-MI animals
ontinued to enlarge, as shown in Fig. 4A). Hemodynamic
nalyses further confirmed the improvement of left ventric-
lar function by the S16EPLN/rAAV strategy (56). Among
ther improvements, the left ventricular end-diastolic pres-
ure, which was considerably elevated in MI-saline rats, was
ear normal in the S16EPLN treatment group (56). In
uantitative histologic analysis, a significantly lower extent
f interstitial fibrosis (Fig. 4I) and suppression of cardio-
yocyte hypertrophy were apparent in the non-infarct
egion in the S16EPLN-treated animals versus the control
roup (56). Taken together, these results indicate that
nhancing calcium cycling by inhibiting PLN was capable
f significantly enhancing multiple independent parameters
f cardiac function even in the setting of the loss of over
0% of the viable myocardium.
LINICAL APPLICATION OF PLN
NHIBITION THERAPY AND OTHER
HERAPIES TO ENHANCE SR CA2 UPTAKE
revious clinical studies questioned the relevancy of the use
f inotropic agents to treat chronic heart failure. There was
vidence that chronic exposure to positive inotropic agents,
uch as catecholamines or phosphodiesterase inhibitors, can
ead to a long-term decrease in cardiac function and an
ssociated decrease in survival (57). Furthermore, adminis-
ration of beta-blockers is now a mainstream heart failure
reatment together with the afterload reduction therapy
ith angiotensin-converting enzyme inhibitors, improving
urvival and the progression of clinical heart failure (58). As
oted in the current review, we consider defects in calcium
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November 7, 2006:A15–23 Reversal of Calcium Defects in Heart Failureycling are a final common pathway for decreases in cardiac
unction in advanced forms of the disease, irrespective of the
tiology. The unique aspect of S16EPLN/rAAV gene
herapy, in contrast with the preceding pharmacologic
notropic agents, is that this therapy targets the most
ownstream point of the regulatory pathway of excitation-
ontraction coupling without chronic increases in cytoplasmic
yclic AMP levels or chronic PKA activation. Accordingly,
hronic improvement of excitation-contraction coupling in a
yclic AMP-independent manner with a high efficiency,
ong-term, and cardiotropic S16EPLN/rAAV gene delivery
ppear to be a novel therapeutic strategy for slowing heart
ailure progression. The inherent cardiac and slow skeletal
uscle specificity determined by the native distribution of
LN is another safety aspect of S16EPLN therapy for
linical applications. It should be also noted that a large
ody of independent work by del Monte and Hajjar (59)
legantly moved forward to work on the potential therapeu-
igure 4. Chronic therapeutic effects of S16EPLN/rAAV-treatment in po
A to C) before and after S16EPLN gene transfer and pulse-wave Doppler
ats (E), and S16EPLN-treated post-MI rats (F). Note elevated early fillin
ormalized in S16EPLN-treated animals. Suppression of the induction of i
bvious (G to I). (G) Sham (no-MI) rat myocardium; (H) Saline-treate
odified from figures in Iwanaga et al. (56). LVEDV  left ventricular e
entricular end-systolic volume.ic role of SERCA2 gene therapy for advanced forms of heart failure, suggesting another approach to target defects
n SR calcium cycling in heart failure.
To translate the SR calcium-targeted therapy to human
linical settings, we have been collaborating with Drs. David
aye and John Powers of Baker Heart Institute in Mel-
ourne, Australia, on the development of a novel clinically
elevant, percutaneous gene delivery system with viral vec-
ors (60). A unique strategy of safe, reproducible, high-
fficient delivery of rAAV vectors (serotype 1 and serotype 2)
o the myocardium of both healthy normal sheep and sheep
ith moderate-to-severe pacing-induced heart failure has
een proven to be very reproducible. The catheter-based
ntracoronary SERCA2 or S16EPLN delivery involves
ecirculation of vectors in a closed-loop system, and this
trategy has been shown to enhance cardiac contractility in
eart failure in sheep.
These studies have set the stage for AAV gene therapy to
nhance calcium cycling as a new therapeutic strategy for
ocardial infarction (MI) rats. Serial changes of echocardiographic variables
ing of mitral flow found in sham (no-MI) rats (D), saline-treated post-MI
city and diminished late filling found in saline-treated post-MI rats were
itial fibrosis in the non-infarcted region in S16EPLN-treated animals was
st-MI rat myocardium; (I) S16EPLN-treated post-MI rat myocardium.
astolic volume; LVEF  left ventricular ejection fraction; LVESV  leftst-my
imag
g velo
nterst
d pouman heart failure, and the design of clinical studies is
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otential for developing small molecule inhibitors of PLN
lso needs to be reconsidered, given recent evidence that
LN actually represents an inhibitory subunit of SERCA
Fig. 3B), supported by recent elegant studies of Mueller
t al. (61) and Zamoon et al. (62). Thus, the potential for
he development of allosteric inhibitors of PLN remains a
eal possibility. New molecular-based strategies for enhanc-
ng calcium cycling appear to be on the horizon and may
ffer new hope for patients with advanced forms of the
isease in the future.
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